Use this URL to cite or link to this record in EThOS:
Title: Novel unconventional T-cells in response to bacteria and cancer
Author: Crowther, Michael
ISNI:       0000 0004 7652 314X
Awarding Body: Cardiff University
Current Institution: Cardiff University
Date of Award: 2018
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Conventional T-cells respond to peptide antigens presented by person-specific Human Leukocyte Antigens (HLAs) and therefore therapies that harness such cells may only be applicable to a minority of individuals. Unconventional T-cells could bypass this limitation to provide an opportunity for population-wide disease treatments. Exploitation of such T-cells first requires a detailed study of the unconventional T-cells involved in the immune response. I therefore sought to characterise novel invariant T-cells generated in response to varied disease agents. Results - An optimised protocol for procurement of disease-relevant unconventional T-cells was established and used to generate T-cell lines and clones of interest. T-cell receptor (TCR) sequencing of unconventional T-cell populations revealed a predominance of mucosal-associated invariant cells and Vγ9Vδ2 T-cells. Enrichments for other shared TCR clonotypes included TRAV21 and TRAV13-1 genes, which have some evidence of an invariant nature. I identified an interesting T-cell clone that was capable of recognising a broad range of target cells through a novel mechanism. The ligand recognised by these T-cells was identified using a whole genome CRISPR approach. Further studies confirmed the nature of the ligand and that recognition was dependent on a new subtype of TCR that was present in all donors tested. Conclusions - The field of unconventional T-cells is rapidly expanding, with novel invariant T-cells proving to be a much greater part of the T-cell repertoire than previously estimated. New and undiscovered invariant T-cell subsets are likely to provide exciting novel immunotherapies and bypass the limitation of HLA-restriction that is associated with conventional T-cell recognition of peptide-major histocompatibility complex ligands.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID:  DOI: Not available